Catherine ANDRÉ


Group leader

Catherine ANDRÉ Group

+33 (0)2 23 23 45 09

Villejean campus / Building 4 / Room 217


  • Member of the CNRS National evaluation committee (2012-2016)
  • Creation and managment of the Cani-DNA Biological Resource Centre (National Biobank of canine samples)
  • Member of the organising committee of the bis-annual international meeting "International dog and cat genomes and genetic diseases"
  • Member of the French academy of Veterinary medicine.
  • Member of PhD defenses at national and international levels ; Expertises for scientific article reviews; and for funding agencies
  • Member of the working group "  "spontaneous models in comparative pathology" at the French Medicine Academy (2012-2015)

In a few words

I'm researcher at CNRS (since 1992), and group leader of the "Canine genetics team" since 2008.

I'm working since 20 years on the developpement of genetic tools, a French veterinary network  and biological resources for the study of the canine genome and the characterization of natural models of human genetic diseases, for the needs of the team and mainly for the international scientific community interested by the canine model for biomedical research.

I participed  to the developpement of markers, genomic and comparative maps,  and finally to the canine genome sequence in 2005.

In parallel, I created and manage a Biological resource centre (Cani-DNA) to collect dog samples  by setting a veterinary network and contracts with the 4 Veterinary Schools and the animal genetics  Company, Antagene. I initiated and developped numerous research projects with the aim to characterize on the clinical, epidemiological, histopathological and genetical aspects the homologies between dog and human for diseases such dermatological conditions (ichthyoses, keratoderma, auto-immune diseases ..), neuro-sensorial (epilepsies, neuropathies, rétinopathies …); and several dog/human homologous cancers  (melanomas, sarcomas, lymphomas, gliomas …). Thus, we have identified new genes, new functions for human genetic diseases and have characterized  spontaneous models for clinical trials "first in dogs" following the "One health" concept

Subscribe to our newsletter